Serum interleukin-15 levels in cancer patients with cachexia

Oncology Reports

Volumn 28, Issue 4, 2012, Pages 1443-1452

  Martínez Hernández, Pedro L ^a   Hernanz Macías, Ángel ^a   Gómez Candela, Carmen ^a   Grande Aragón, Cristina ^a   Feliu Batlle, Jaime ^a   Castro Carpeño, Javier ^a   Martínez Muñoz, Isabel ^a   Zurita Rosa, Laura ^a   Villarino Sanz, Marta ^a   Prados Sánchez, Concepción ^a   García Girón, Joaquín Sánchez ^a  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

Author keywords

Body weight; Cachexia; Cancer; Fat free mass; Interleukin 15; Muscle mass

Indexed keywords

INTERLEUKIN 15;

ADULT; ARTICLE; BODY COMPOSITION; BODY MASS; CACHEXIA; CANCER PATIENT; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; FEMALE; HUMAN; MALE; MUSCLE MASS; OBSERVATIONAL STUDY; PATHOGENESIS; PATHOPHYSIOLOGY; PATIENT ASSESSMENT; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; WEIGHT CHANGE; WEIGHT REDUCTION;

ADULT; AGED; BODY COMPOSITION; BODY WEIGHT; CACHEXIA; CASE-CONTROL STUDIES; FEMALE; HUMANS; INTERLEUKIN-15; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASMS; REFERENCE VALUES; WEIGHT LOSS; YOUNG ADULT;

EID: 84866443782     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2012.1928     Document Type: Article

References (53)

1. Fearon KC, Voss AC and Hustead DS: Definition of cancer cachexia: effect of weight loss, reduced food intake, and systemic inflammation on functional status and prognosis. Am J Clin Nutr 83: 1345-1350, 2006.
2. Evans WJ, Morley JE, Argilés J, Bales C, Baracos V, Guttridge D, Jatoi A, Kalantar-Zadeh K, Lochs H, Mantovani G, et al: Cachexia: a new definition. Clin Nutr 27: 793-799, 2008
3. Tisdale MJ: Pathogenesis of cancer cachexia. J Support Oncol 1: 159-168, 2003.
4. Morley JE, Thomas DR and Wilson MMG: Cachexia: pathophysiology and clinical relevance. Am J Clin Nutr 83: 735-743, 2006.
5. Dewys WD, Begg C, Lavin PT, Band PR, Bennett JM, Bertino JR, Cohen MH, Douglass HO Jr, Engstrom PF, Ezdinli EZ, et al: Prognostic effect of weight loss prior to chemotherapy in cancer patients. Eastern Cooperative Oncology Group. Am J Med 69: 491-497, 1980.
6. Haehling S and Anker SD: Cachexia as a major underestimated and unmet medical need: facts and nunber. J Cachexia Sarcopenia Muscle 1: 1-5, 2010.
7. Grabstein K, Eisenman J, Shanebeck K, Rauch C, Srinivasan S, Fung V, Beers C, Richardson J, Schoenborn MA, Ahdieh M, et al: Cloning of a T cell growth factor that interacts with the β chain of the interleukin-2 receptor. Science 264: 965-968, 1994.
8. Burton JD, Bamford RN, Peters C, Grant AJ, Kurys G, Goldman CK, Brennan J, Roessler E and Waldmann TA: A lymphokine, provisionally designed interleukin T and produced by a human adult T-cell leukemia line, stimulates T-cell proliferation and the induction of lymphokine-activated killer cells. Proc Natl Acad Sci USA 91: 4935-4939, 1994.
9. Giri JG, Ahdieh M, Eisenman J, Shanebeck K, Grabstein K, Kumaki S, Namen A, Park LS, Cosman D and Anderson D: Utilization of the beta and gamma chains of the IL-2 receptor by the novel cytokine IL-15. EMBO J 13: 2822-2830, 1994.
10. Quinn LS, Haugk KL and Grabstein KH: Interleukin-15: a novel anabolic cytokine for skeletal muscle. Endocrinology 136: 3669-3672, 1995.
11. Quinn LS, Anderson BG, Drivdahl RH, Alvarez B and Argilés JM: Overexpression of interleukin-15 induces skeletal muscle hypertrophy in vitro: implications for treatment of muscle wasting disorders. Exp Cell Res 280: 55-63, 2002.
12. Carbó N, López-Soriano J, Costelli P, Busquets S, Alvarez B, Baccino FM, Quinn LS, López-Soriano FJ and Argilés JM: Interleukin-15 antagonizes muscle protein waste in tumour-bearing rats. Br J Cancer 83: 526-531, 2000.
13. Van Royen M, Carbó N, Busquets S, Alvarez B, Quinn LS, López-Soriano FJ and Argilés JM: DNA fragmentation occurs in skeletal muscle during tumor growth: a link with cancer cachexia? Biochem Biophys Res Commun 270: 533-537, 2000.
14. Figueras M, Busquets S, Carbó N, Barreiro E, Almendro V, Argilés JM and López-Soriano FJ: Interleukin-15 is able to suppress the increased DNA fragmentation associated with muscle wasting in tumour-bearing rats. FEBS Lett 569: 201-206, 2004.
15. Busquets S, Almendro V, Barreiro E, Figueras M, Argilés JM and López-Soriano FJ: Activation of UCPs gene expression in skeletal muscle can be independent on both circulating fatty acids and food intake. Involvement of ROS in a model of mouse cancer cachexia. FEBS Lett 579: 717-722, 2005.
16. Zubrod CG, Scheneidermann M, Frei E, Brindley C, Gold GL, Shnider B, Oviedo R, Gorman J, Jones R Jr, Jonsson U, et al: Appraisal of methods for the study of chemotherapy of cancer in man: comparative therapeutic trial of nitrogen mustard and trietylene thiophosphoramide. J Chron Dis 11: 7-33, 1960.
17. Utter AC, Nieman DC, Ward AN and Butterworth DE: Use of the leg-to-leg bioelectrical impedance method in assessing body-composition change in obese women. Am J Clin Nutr 69: 603-607, 1999.
18. Ordóñez A, Feijoo M and González Barón M: Evaluación de la Astenia. In: Valoración clínica del paciente con cáncer. González Barón M, Lacasta MA and Ordóñez A (eds). Editorial Médica Panamericana, S.A. Madrid, pp79-87, 2006.
19. ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories: ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med 166: 111-117, 2002.
20. Katz A, Nambi SS, Mather K, Baron AD, Follmann DA, Sullivan G and Quon MJ: Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans. J Clin Endocrinol Metab 85: 2402-2410, 2000.
21. Fearon K, Strasser F, Anker SD, Bosaeus I, Bruera E, Fainsinger RL, Jatoi A, Loprinzi C, MacDonald N, Mantovani G, et al: Definition and classification of cancer cachexia: and international consensus. Lancet Oncol 12: 489-495, 2011.
22. Lambert CP, Flynn MG, Sullivan DH and Evans WJ: Effects of megestrol acetate on circulating interleukin-15 and interleukin-18 concentrations in healthy elderly men. J Gerontol A Biol Sci Med Sci 59: 855-858, 2004.
23. Riechman SE, Balasekaran G, Roth SM and Ferrel RE: Association of interleukin-15 protein and interleukin-15 receptor genetic variation with resistance exercise training responses. J Appl Physiol 97: 2214-2219, 2004.
24. Spatari G, Fenga C, Minciullo PL, Di Pasquale G, Cacciola A, Ventura-Spagnolo E and Gangemi S: Modification of interleukin-15 serum levels in workers exposed to chemotherapeutic agents. Mediators Inflamm 1: 60-62, 2005.
25. Gangemi S, Basile G, Monti D, Merendino RA, Di Pasquale G, Bisignano U, Nicita-Mauro V and Franceschi C: Age-related modifications in circulating IL-15 levels in humans. Mediators Inflamm 4: 245-247, 2005.
26. Yamaji K, Nabeshima S, Murata M, Chong Y, Furusyo N, Ikematsu H and Hayashi J: Interferon-α/β upregulate IL-15 expression in vitro and in vivo: analysis in human hepatocellular carcinoma cell lines and in chronic hepatitis C patients during interferon-α/β treatment. Cancer Immunol Immunother 55: 394-403, 2006.
27. Nielsen AR, Mounier R, Plomgaard P, Mortensen OH, Penkowa M, Speerschneider T, Pilegaard H and Pedersen BK: Expression of interleukin-15 in human skeletal muscle-effect of excercise and muscle fibre type composition. J Physiol 584: 305-312, 2007.
28. Nielsen AR, Hojman P, Erikstrup C, Fischer CP, Plomgaard P, Mounier R, Mortensen OH, Broholm C, Taudorf S, Krogh-Madsen R, et al: Association between interleukin-15 and obesity: interleukin-15 as a potential regulator of fat mass. J Clin Endocrinol Metab 93: 4486-4493, 2008.
29. Lamana A, Ortiz AM, Alvaro-Gracia JM, Díaz-Sánchez B, Novalbos J, García-Vicuña R and González-Alvaro I: Characterization of serum interleukin-15 in healthy volunteers and patients with early arthritis to assess its potential use as a biomarker. Eur Cytokine Netw 21: 186-194, 2010.
30. Lissoni P, Rovelli F, Mandala M and Barni S: Blood concentrations of interleukin-15 in cancer patients and their variations during interleukin-2 immunotherapy: preliminary considerations. Int J Biol Markers 13: 169-171, 1998.
31. Pappa C, Miyakis S, Tsirakis G, Sfiridaki A, Alegakis A, Kafousi M, Stathopoulos EN and Alexandrakis MG: Serum levels of interleukin-15 and interleukin-10 and their correlation with proliferating cell nuclear antigen in multiple myeloma. Cytokine 37: 171-175, 2007.
32. Kakumu S, Okumura A, Ishikawa T, Yano M, Enomoto A, Nishimura H, Yoshioka K and Yoshika Y: Serum levels of IL-10, IL-15 and soluble tumour necrosis factor-alpha (TNF-α) receptors in type C chronic liver disease. Clin Exp Immunol 109: 458-463, 1997.
33. Sugaya M, Nakamura K and Tamaki K: Serum interleukin-15 levels are not elevated in patients with stage I and II mycosis fungoides. Acta Derm Venereol 80: 455, 2000.
34. Badoual C, Bouchand G, Agueznay NEH, Mortier E, Hans S, Gey A, Fernani F, Peyrard S, Laurent-Puig P, Bruneval P, et al: The soluble alpha chain of interleukin-15 receptor: a proinflammatory molecule associated with tumor progression in head and neck cancer. Cancer Res 68: 3907-3914, 2008.
35. Porrata LF, Inwards DJ, Micallef IN, Johnston PB, Ansell SM, Hogan WJ and Markovic SN: Interleukin-15 affects patient survival through natural killer cell recovery after autologous hematopoietic stem cell transplantation for non-Hodgkin lymphomas. Clin Dev Immunol doi: 10.1155/2010/914945, 2010.
36. Wu S, Fischer L, Gökbuget N, Schwartz S, Burmeister T, Notter M, Hoelzer D, Fuchs H, Blau IW, Hofmann WK and Thiel E: Expression of interleukin-15 in primary adult acute lymphoblastic leukemia. Cancer 116: 387-392, 2010.
37. Kuczynski S, Winiarska H, Abramczyck M, Szczawinska K, Wierusz-Wysocka B and Dworacka M: IL-15 is elevated in serum patients with type 1 diabetes mellitus. Diabetes Res Clin Pract 69: 231-236, 2005.
38. Prestes J, Shiguemoto G, Botero JP, Frollini A, Dias R, Leite R, Pereira G, Magosso R, Baldissera V, Cavaglieri C and Perez S: Effects of resistance training on resistin, leptin, cytokines, and muscle force in elderly post-menopausal women. J Sports Sci 27: 1607-1615, 2009.
39. Grzegorzewska AE, Mlot M and Leander M: Serum levels of cancer antigen 125 and interleukin-15 in relation to the nutrition status of peritoneal dialysis patients. Adv Perit Dial 20: 185-189, 2004.
40. Carbó N, López-Soriano J, Costelli P, Alvarez B, Busquets S, Baccino FM, Quinn LS, López-Soriano FJ and Argilés JM: Interleukin-15 mediates reciprocal regulation of adipose and muscle mass: a potential role in body weight control. Biochim Biophys Acta 1526: 17-24, 2001.
41. Alvarez B, Carbó N, López-Soriano J, Drivdahl RH, Busquets S, López-Soriano FJ, Argilés JM and Quinn LS: Effects of interleukin-15 (IL-15) on adipose tissue mass in rodent obesity models: evidence for direct IL-15 action on adipose tissue. Biochim Biophys Acta 1570: 33-37, 2002.
42. Quinn LS, Strait-Bodey L, Anderson BG, Argilés JM and Havel PJ: Interleukin-15 stimulates adiponectin secretion by 3T3-L1 adipocytes: evidence for a skeletal muscle-to-fat signalling pathway. Cell Biol Int 29: 449-457, 2005.
43. Geller MA, Cooley S, Judson PL, Ghebre R, Carson LF, Argenta PA, Jonson AL, Panoskaltsis-Mortari A, Curtsinger J, McKenna D, et al: A phase II study of allogeneic natural killer cell therapy to treat patients with recurrent ovarian and breast cancer. Cytotherapy 13: 98-107, 2011.
44. Dudley ME, Yang JC, Sherry R, Hughes MS, Royal R, Kammula U, Robbins PF, Huang JP, Citrin DE, Leitman SF, et al: Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J Clin Oncol 26: 5233-5239, 2008.
45. Busquets S, Figueras MT, Meijsing S, Carbó N, Quinn LS, Almendro V, Argilés JM and López-Soriano FJ: Interleukin-15 decreases proteolysis in skeletal muscle: a direct effect. Int J Mol Med 16: 471-476, 2005.
46. Kadowaki M and Kanazawa T: Amino acids as regulators of proteolysis. J Nutr 133: S2052-S2056, 2003.
47. Garlick PJ: The role of leucine in the regulation of protein metabolism. J Nutr 135: S1553-S1556, 2005.
48. Mitch WE and Goldberg AL: Mechanisms of muscle wasting. The role of the ubiquitin-proteasome pathway. N Engl J Med 335: 1897-1905, 1996.
49. Thomson R, Brinkworth GD, Buckley JD, Noakes M and Clifton PM: Good agreement between bioelectrical impedance and dual-energy X-ray absorptiometry for estimating changes in body composition during weight loss in overweight young women. Clin Nutr 26: 771-777, 2007.
50. Evans WJ: Skeletal muscle loss: cachexia, sarcopenia, and inactivity. Am J Clin Nutr 91: S1123-S1127, 2010.
51. Malina RM: Variation in body composition associated with sex and ethnicity. In: Human Body Composition. Heymsfield SB, Lohman TG, Wang ZM and Going SB (eds). 2nd edition. McGraw-Hill Interamericana Editores, S.A. Mexico, pp271-298, 2007.
52. Rentzos M, Paraskevas GP, Kapaki E, Nikolaou C, Zoga M, Tsoutsou A, Rombos A and Vassilopoulos D: Circulating interleukin-15 in dementia disorders. J Neuropsychiatry Clin Neurosci 19: 318-325, 2007.
53. Argilés JM, López-Soriano FJ and Busquets S: Therapeutic potential of interleukin-15: a myokine involved in muscle wasting and adiposity. Drug Discov Today 14: 208-213, 2009.